Merck & Co., Inc. $MRK Stake Boosted by Whitener Capital Management Inc.

Whitener Capital Management Inc. lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 10.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 50,378 shares of the company’s stock after buying an additional 4,958 shares during the quarter. Merck & Co., Inc. makes up approximately 1.3% of Whitener Capital Management Inc.’s portfolio, making the stock its 16th biggest position. Whitener Capital Management Inc.’s holdings in Merck & Co., Inc. were worth $7,320,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Round Rock Advisors LLC raised its holdings in Merck & Co., Inc. by 0.7% in the second quarter. Round Rock Advisors LLC now owns 9,901 shares of the company’s stock valued at $1,272,000 after acquiring an additional 66 shares in the last quarter. Cascade Financial Partners LLC lifted its stake in Merck & Co., Inc. by 0.5% in the second quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock worth $1,895,000 after acquiring an additional 80 shares during the last quarter. Somerset Trust Co grew its holdings in Merck & Co., Inc. by 0.9% during the 2nd quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock worth $1,118,000 after acquiring an additional 81 shares in the last quarter. Stonebridge Financial Group LLC grew its holdings in Merck & Co., Inc. by 0.9% during the 2nd quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company’s stock worth $1,124,000 after acquiring an additional 81 shares in the last quarter. Finally, Stronghold Wealth Management L.L.C. grew its holdings in Merck & Co., Inc. by 2.6% during the 2nd quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company’s stock worth $416,000 after acquiring an additional 82 shares in the last quarter. 76.07% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Trading Down 1.2%

Shares of Merck & Co., Inc. stock opened at $145.66 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The company has a fifty day simple moving average of $145.26 and a 200-day simple moving average of $129.12. The stock has a market cap of $359.37 billion, a price-to-earnings ratio of 116.53, a PEG ratio of 6.81 and a beta of 0.21. Merck & Co., Inc. has a 12-month low of $82.01 and a 12-month high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same period last year, the business earned $2.13 EPS. Merck & Co., Inc.’s revenue for the quarter was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities analysts forecast that Merck & Co., Inc. will post 2.66 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th were issued a dividend of $0.85 per share. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.3%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 272.00%.

Insider Activity at Merck & Co., Inc.

In other news, EVP Richard Deluca sold 20,784 shares of Merck & Co., Inc. stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the sale, the executive vice president owned 134,703 shares in the company, valued at approximately $17,569,312.29. The trade was a 13.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Jennifer Zachary sold 80,315 shares of the business’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the sale, the executive vice president directly owned 45,509 shares of the company’s stock, valued at $6,073,631.14. The trade was a 63.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 228,238 shares of company stock valued at $29,977,783. Corporate insiders own 0.17% of the company’s stock.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck plans to present first-time pivotal Phase 3 data at ESMO 2026 for oncology programs including melanoma and endometrial cancer. The company will also hold an oncology investor event, potentially giving investors greater visibility into growth opportunities beyond Keytruda. What Could Merck Reveal At ESMO 2026 About Its Oncology Pipeline?
• Positive Sentiment: CEO Rob Davis said Merck and Moderna expect manufacturing of their personalized cancer vaccine to become faster over time. Improving production efficiency could support broader commercialization of the vaccine, although manufacturing remains complex. Merck CEO Tells CNBC He Expects Breakthrough Cancer Vaccine Will Become Faster to Make
• Neutral Sentiment: Analysts expect Keytruda sales growth, newer product launches and expanded indications to support third-quarter revenue. However, biosimilar competition is expected to become a more significant risk in 2028–2029, making pipeline execution increasingly important. Will Keytruda Continue to Aid Merck’s Top Line in Q3 Earnings?
• Neutral Sentiment: Merck’s dividend yield is about 2.3%, but comparisons with Amgen highlight differing levels of dividend coverage and cash-flow flexibility. The analysis may influence income-focused investors but does not introduce a new company-specific catalyst. AMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow
• Negative Sentiment: Merck trades at a premium valuation of roughly 5.5 times sales, increasing the market’s expectations for sustained growth. Investors are also monitoring the changing emphasis in management’s strategy and continuing challenges for the Gardasil vaccine business in China. How Has Merck’s Story Changed?

Wall Street Analyst Weigh In

A number of brokerages have commented on MRK. Wolfe Research increased their price objective on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a research report on Tuesday, August 25th. Scotiabank lifted their price objective on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, September 29th. Leerink Partners boosted their target price on shares of Merck & Co., Inc. from $127.00 to $161.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 9th. The Goldman Sachs Group boosted their target price on shares of Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a “buy” rating in a research note on Friday, August 21st. Finally, Citigroup increased their target price on Merck & Co., Inc. from $125.00 to $145.00 and gave the company a “neutral” rating in a report on Monday. Seventeen equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $151.92.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.